text:
Our Focus >
Our Research >
Our Medicine >
INVESTORS & MEDIA >
Intercept Pharmaceuticals Reports Fourth Quarter & Full Year 2018 Financial Results, Issues 2019 Financial Guidance & Provides Business Update
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Issues 2019 Financial Guidance and Provides Business Update
Positive topline results from pivotal Phase 3 REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH: the largest and first successful pivotal Phase 3 NASH study
Worldwide Ocaliva net sales of $52.9 million in the fourth quarter of 2018 and $177.8 million in the full year 2018, consistent with previously issued guidance
Strong year-end cash position of approximately $436.2 million
2019 worldwide Ocaliva net sales projected between $225 million and $240 million and 2019 non-GAAP adjusted operating expenses projected between $450 million and $470 million
Conference call scheduled for 8:30 a.m. ET today
NEW YORK, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2018.
"This past year was a great year of execution against our key strategic priorities in our Phase 3 NASH program and our PBC commercial efforts," said Mark Pruzanski, M.D., President and Chief Executive Officer of Intercept. "We were thrilled to recently report positive topline data from our pivotal Phase 3 REGENERATE study, with OCA clearly meeting the study's primary objective by demonstrating its anti-fibrotic benefit in patients with NASH, truly a first in the field. We intend to file for regulatory approval in the U.S. and Europe in the second half of this year and believe that the REGENERATE results support our long-held conviction that OCA will become the first approved medicine and backbone therapy for those living with liver fibrosis due to NASH. This underscores our ongoing commitment to drive scientific innovation to address the unmet medical needs of patients with progressive non-viral liver diseases, both large and small."
Ocaliva® (obeticholic acid or OCA) Commercial Highlights
We recognized $52.9 million of Ocaliva net sales in the fourth quarter of 2018, as compared to $37.3 million in the prior year quarter. Ocaliva net sales in the fourth quarter of 2018 were comprised of U.S. net sales of $41.1 million and ex-U.S. net sales of $11.8 million, as compared to U.S. net sales of $32.0 million and ex-U.S. net sales of $5.3 million in the prior year quarter.
Full year 2018 Ocaliva net sales were $177.8 million, as compared to $129.2 million in 2017. Ocaliva net sales in 2018 were comprised of U.S. net sales of $140.8 million and ex-U.S. net sales of $37.0 million, as compared to U.S. net sales of $115.8 million and ex-U.S. net sales of $13.4 million in 2017.
Ocaliva was approved in the United States by the U.S. Food and Drug Administration ("FDA") in May 2016 for the treatment of primary biliary cholangitis ("PBC") in combination with ursodeoxycholic acid ("UDCA") in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. We commenced sales and marketing of Ocaliva in the United States shortly after receiving marketing approval, and Ocaliva is now available to patients primarily through a network of specialty pharmacy distributors.
Ocaliva was granted conditional approval by the European Commission in December 2016 for the treatment of PBC in combination with UDCA in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA, and we commenced our European commercial launch in January 2017. Since January 2017, Ocaliva has also received regulatory approval in several of our target markets outside the United States and Europe, including Canada, Israel and Australia.
Selected Fourth Quarter and Full Year 2018 Financial Results
We recognized $53.3 million in total revenue in the fourth quarter of 2018, as compared to $37.7 million in total revenue in the prior year quarter. Total revenue in the fourth quarter of 2018 included $52.9 million of Ocaliva net sales and approximately $0.4 million of licensing revenue, as compared to $37.3 million and approximately $0.4 million, respectively, in the prior year quarter.
We recognized $179.8 million in total revenue in 2018, as compared to $131.0 million in 2017. Total revenue in 2018 included $177.8 million of Ocaliva net sales and approximately $2.0 million of licensing revenue, as compared to $129.2 million and approximately $1.8 million, respectively, in 2017. Included in total revenue in 2017 was $4.1 million of previously deferred revenue recognized in connection with our adoption of a sell-in basis revenue recognition policy in 2017.
Our cost of sales was $1.0 million in the fourth quarter of 2018, as compared to $0.8 million in the prior year quarter. Cost of sales was $2.5 million in 2018, as compared to $1.4 million in 2017. Our cost of sales for the quarters and years ended December 31, 2018 and 2017 consisted primarily of packaging and labeling expenses.
Our selling, general and administrative expenses decreased to $71.0 million in the fourth quarter of 2018, down from $84.3 million in the prior year quarter. Selling, general and administrative expenses decreased to $255.5 million in 2018, down from $273.7 million in 2017. The fourth quarter and full year period-over-period decreases were both primarily driven by a lease termination fee and restructuring-related charges incurred in December 2017.
Our research and development expenses increased to $63.3 million in the fourth quarter of 2018, up from $57.5 million in the prior year quarter. Research and development expenses increased to $207.3 million in 2018, up from $191.5 million in 2017. The fourth quarter and full year period-over-period increases were both primarily driven by a $9.0 million payment made in December 2018 in connection with our acquisition from Aralez Pharmaceuticals Canada Inc. of its license to develop and commercialize bezafibrate in the United States.
In the quarters ended December 31, 2018 and 2017, we recorded $135.3 million and $142.7 million, respectively, in total operating expenses and $122.7 million and $125.9 million, respectively, in non-GAAP adjusted operating expenses, which excludes non-cash stock-based compensation expense of $11.5 million and $15.4 million, respectively, and depreciation expense of $1.0 million and $1.3 million, respectively.
In the years ended December 31, 2018 and 2017, we recorded $465.3 million and $466.6 million, respectively, in total operating expenses and $410.8 million and $405.0 million, respectively, in non-GAAP adjusted operating expenses, which excludes non-cash stock-based compensation expense of $49.9 million and $57.0 million, respectively, and depreciation expense of $4.6 million and $4.6 million, respectively.
References in this press release to "non-GAAP adjusted operating expenses" mean our total operating expenses, as calculated and presented in accordance with U.S. Generally Accepted Accounting Principles ("GAAP"), adjusted for the effects of two non-cash items: stock-based compensation and depreciation. See "Non-GAAP Financial Measures" below. A reconciliation of non-GAAP adjusted operating expenses to total operating expenses for all historical periods presented is included below under the heading "Reconciliation of Non-GAAP Adjusted Operating Expenses to Total Operating Expenses".
Interest expense in the quarters ended December 31, 2018 and 2017 was $7.8 million and $7.4 million, respectively. Interest expense in the years ended December 31, 2018 and 2017 was $30.5 million and $29.3 million, respectively. Our interest expense is related to the $460.0 million aggregate principal amount of 3.25% Convertible Senior Notes due 2023 (the "Convertible Notes") that we issued in July 2016.
In the fourth quarter and full year 2018, we reported a net loss of $88.0 million and $309.2 million, respectively, down from a net loss of $111.3 million and $360.4 million in the fourth quarter and full year 2017.
As of December 31, 2018, we had cash, cash equivalents and investment securities available for sale of approximately $436.2 million. As of December 31, 2017, we had cash, cash equivalents and investment securities available for sale of approximately $414.9 million.
2019 Financial Guidance
We are announcing our 2019 Ocaliva net sales guidance range of between $225 million and $240 million. In addition, we are announcing our 2019 non-GAAP adjusted operating expenses guidance range of between $450 million and $470 million, which includes expected resources to support our NASH filing and launch preparation activities. See "Non-GAAP Financial Measures" below. A quantitative reconciliation of projected non-GAAP adjusted operating expenses to total operating expenses is not available without unreasonable effort primarily due to our inability to predict with reasonable certainty the amount of future stock-based compensation expense.
Conference Call on February 28, 2019 at 8:30 a.m. ET
We are hosting our fourth quarter and full year 2018 financial results conference call and webcast on Thursday, February 28, 2019 at 8:30 a.m. ET. The conference call will be available on the investor page of our website at http://ir.interceptpharma.com or by calling (855) 232-3919 (toll-free domestic) or (315) 625-6894 (international) five minutes prior to the start time (no passcode is required). A replay of the call will be available on our website shortly following the completion of the call and will be available for two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.
This press release presents non-GAAP adjusted operating expenses on a historical and projected basis. For the periods presented, non-GAAP adjusted operating expenses exclude from total operating expenses, as calculated and presented in accordance with GAAP, the effects of two non-cash items: stock-based compensation and depreciation. Non-GAAP adjusted operating expenses is a financial measure that has not been prepared in accordance with GAAP. Accordingly, investors should consider non-GAAP adjusted operating expenses in addition to, but not as a substitute for, total operating expenses that we calculate and present in accordance with GAAP. Among other things, our management uses non-GAAP adjusted operating expenses to establish budgets and operational goals and to manage our business. Other companies may define or use this measure in different ways. We believe that the presentation of non-GAAP adjusted operating expenses provides investors and management with helpful supplemental information relating to operating performance and trends. A table reconciling non-GAAP adjusted operating expenses to total operating expenses for all historical periods presented is included below under the heading "Reconciliation of Non-GAAP Adjusted Operating Expenses to Total Operating Expenses". A quantitative reconciliation of projected non-GAAP adjusted operating expenses to total operating expenses is not available without unreasonable effort primarily due to our inability to predict with reasonable certainty the amount of future stock-based compensation expense.
About Ocaliva® (obeticholic acid)
Ocaliva is indicated in the United States for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
This indication is approved under accelerated approval based on a reduction in alkaline phosphatase (ALP) as a surrogate endpoint which is reasonably likely to predict clinical benefit, including an improvement in liver transplant free-survival. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. We are conducting a Phase 4 clinical outcomes trial, which we refer to as our COBALT trial, of OCA in patients with PBC with the goal of confirming clinical benefit on a post-marketing basis.
In December 2016, Ocaliva received conditional marketing authorization in Europe for the treatment of PBC in combination with UDCA in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA, conditioned upon us providing further data post-approval to confirm benefit. For detailed safety information for Ocaliva 5 mg and 10 mg tablets including posology and method of administration, special warnings, drug interactions and adverse drug reactions, please see the European Summary of Product Characteristics that can be found on www.ema.europa.eu.
U.S. IMPORTANT SAFETY INFORMATION
WARNING: HEPATIC DECOMPENSATION AND FAILURE IN INCORRECTLY DOSED PBC PATIENTS WITH CHILD-PUGH CLASS B OR C OR DECOMPENSATED CIRRHOSIS
In postmarketing reports, hepatic decompensation and failure, in some cases fatal, have been reported in patients with Primary Biliary Cholangitis (PBC) with decompensated cirrhosis or Child-Pugh Class B or C hepatic impairment when OCALIVA was dosed more frequently than recommended.
The recommended starting dosage of OCALIVA is 5 mg once weekly for patients with Child-Pugh Class B or C hepatic impairment or a prior decompensation event.
OCALIVA is contraindicated in patients with complete biliary obstruction.
Hepatic Decompensation and Failure in Incorrectly-Dosed PBC Patients with Child-Pugh Class B or C or Decompensated Cirrhosis
In postmarketing reports, hepatic decompensation and failure, in some cases fatal, have been reported in patients with decompensated cirrhosis or Child-Pugh B or C hepatic impairment when OCALIVA was dosed more frequently than the recommended starting dosage of 5 mg once weekly. Reported cases typically occurred within 2 to 5 weeks after starting OCALIVA and were characterized by an acute increase in total bilirubin and/or ALP concentrations in association with clinical signs and symptoms of hepatic decompensation (e.g., ascites, jaundice, gastrointestinal bleeding, worsening of hepatic encephalopathy).
Routinely monitor patients for progression of PBC disease, including liver-related complications, with laboratory and clinical assessments. Dosage adjustment, interruption or discontinuation may be required. Close monitoring is recommended for patients at an increased risk of hepatic decompensation. Severe intercurrent illnesses that may worsen renal function or cause dehydration (e.g., gastroenteritis), may exacerbate the risk of hepatic decompensation. Interrupt treatment with OCALIVA in patients with laboratory or clinical evidence of worsening liver function indicating risk of decompensation, and monitor the patient's liver function. Consider discontinuing OCALIVA in patients who have experienced clinically significant liver-related adverse reactions. Discontinue OCALIVA in patients who develop complete biliary obstruction.
Liver-Related Adverse Reactions
Dose-related, liver-related adverse reactions including jaundice, worsening ascites and primary biliary cholangitis flare have been observed in clinical trials, as early as one month after starting treatment with OCALIVA 10 mg once daily up to 50 mg once daily (up to 5-times the highest recommended dosage). Monitor patients during treatment with OCALIVA for elevations in liver biochemical tests and for the development of liver-related adverse reactions.
Severe Pruritus
Severe pruritus was reported in 23% of patients in the OCALIVA 10 mg arm, 19% of patients in the OCALIVA titration arm, and 7% of patients in the placebo arm in a 12-month double-blind randomized controlled trial of 216 patients. Severe pruritus was defined as intense or widespread itching, interfering with activities of daily living, or causing severe sleep disturbance, or intolerable discomfort, and typically requiring medical interventions. Consider clinical evaluation of patients with new onset or worsening severe pruritus. Management strategies include the addition of bile acid resins or antihistamines, OCALIVA dosage reduction, and/or temporary interruption of OCALIVA dosing.
Reduction in HDL-C
Patients with PBC generally exhibit hyperlipidemia characterized by a significant elevation in total cholesterol primarily due to increased levels of high-density lipoprotein-cholesterol (HDL-C). Dose-dependent reductions from baseline in mean HDL-C levels were observed at 2 weeks in OCALIVA-treated patients, 20% and 9% in the 10 mg and titration arms, respectively, compared to 2% in the placebo arm. Monitor patients for changes in serum lipid levels during treatment. For patients who do not respond to OCALIVA after 1 year at the highest recommended dosage that can be tolerated (maximum of 10 mg once daily), and who experience a reduction in HDL-C, weigh the potential risks against the benefits of continuing treatment.
The most common adverse reactions from subjects taking OCALIVA were pruritus, fatigue, abdominal pain and discomfort, rash, oropharyngeal pain, dizziness, constipation, arthralgia, thyroid function abnormality, and eczema.
Bile Acid Binding Resins
Bile acid binding resins such as cholestyramine, colestipol, or colesevelam adsorb and reduce bile acid absorption and may reduce the absorption, systemic exposure, and efficacy of OCALIVA. If taking a bile acid binding resin, take OCALIVA at least 4 hours before or 4 hours after taking the bile acid binding resin, or at as great an interval as possible.
The International Normalized Ratio (INR) decreased following coadministration of warfarin and OCALIVA. Monitor INR and adjust the dose of warfarin, as needed, to maintain the target INR range when coadministering OCALIVA and warfarin.
CYP1A2 Substrates with Narrow Therapeutic Index
Obeticholic acid, the active ingredient in OCALIVA, may increase the exposure to concomitant drugs that are CYP1A2 substrates. Therapeutic monitoring of CYP1A2 substrates with a narrow therapeutic index (e.g. theophylline and tizanidine) is recommended when coadministered with OCALIVA.
Inhibitors of Bile Salt Efflux Pump
Avoid concomitant use of inhibitors of the bile salt efflux pump (BSEP) such as cyclosporine. Concomitant medications that inhibit canalicular membrane bile acid transporters such as the BSEP may exacerbate accumulation of conjugated bile salts including taurine conjugate of obeticholic acid in the liver and result in clinical symptoms. If concomitant use is deemed necessary, monitor serum transaminases and bilirubin.
Please see Full Prescribing Information, including Boxed WARNING and Medication Guide for OCALIVA.
To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals, Inc. at 1-844-782-ICPT or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
This press release contains forward-looking statements, including, but not limited to, statements regarding the progress, timing and results of our clinical trials, including our clinical trials for the treatment of nonalcoholic steatohepatitis ("NASH"), the safety and efficacy of our approved product, Ocaliva (obeticholic acid or "OCA") for primary biliary cholangitis ("PBC"), and our product development candidates, including OCA for NASH, the timing and acceptance of our potential regulatory filings and potential approval of OCA for NASH or any other indications in addition to PBC, the timing and potential commercial success of OCA and any other product candidates we may develop and our strategy, future operations, future financial position, future revenue, projected costs, financial guidance, prospects, plans, objectives of management and expected market growth.
These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "possible," "continue" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement except as required by law. These forward-looking statements are based on estimates and assumptions by our management that, although believed to be reasonable, are inherently uncertain and subject to a number of risks. The following represent some, but not necessarily all, of the factors that could cause actual results to differ materially from historical results or those anticipated or predicted by our forward-looking statements: our ability to successfully commercialize Ocaliva for PBC; our ability to maintain our regulatory approval of Ocaliva for PBC in the United States, Europe, Canada, Israel, Australia and other jurisdictions in which we have or may receive marketing authorization; the initiation, timing, cost, conduct, progress and results of our research and development activities, preclinical studies and clinical trials, including any issues, delays or failures in identifying patients, enrolling patients, treating patients, meeting specific endpoints in the jurisdictions in which we intend to seek approval or completing and timely reporting the results of our NASH or PBC clinical trials; our ability to timely and cost-effectively file for and obtain regulatory approval of our product candidates, including OCA for NASH, in the United States, Europe and our other target markets; conditions that may be imposed by regulatory authorities on our marketing approvals for our products and product candidates, such as the need for clinical outcomes data (and not just results based on achievement of a surrogate endpoint), and any related restrictions, limitations and/or warnings contained in the label of any of our products or product candidates; any potential side effects associated with Ocaliva for PBC, OCA for NASH or our other product candidates that could delay or prevent approval, require that an approved product be taken off the market, require the inclusion of safety warnings or precautions or otherwise limit the sale of such product or product candidate; our ability to establish and maintain relationships with, and the performance of, third-party manufacturers, contract research organizations and other vendors upon whom we are substantially dependent for, among other things, the manufacture and supply of our products, including Ocaliva for PBC and, if approved, OCA for NASH, and our clinical trial activities; our ability to identify, develop and successfully commercialize our products and product candidates, including our ability to timely and successfully launch OCA for NASH, if approved; our ability to obtain and maintain intellectual property protection for our products and product candidates, including our ability to cost-effectively file, prosecute, defend and enforce any patent claims or other intellectual property rights; the size and growth of the markets for our products and product candidates and our ability to serve those markets; the degree of market acceptance of Ocaliva for PBC and, if approved, OCA for NASH or our other product candidates among physicians, patients and healthcare payors; the availability of adequate coverage and reimbursement from governmental and private healthcare payors for our products, including Ocaliva for PBC and, if approved, OCA for NASH, and our ability to obtain adequate pricing for such products; our ability to establish and maintain effective sales, marketing and distribution capabilities, either directly or through collaborations with third parties; competition from existing drugs or new drugs that become available; our ability to prevent system failures, data breaches or violations of data protection laws; costs and outcomes relating to any disputes, governmental inquiries or investigations, legal proceedings or litigation, including any securities, intellectual property, employment, product liability or other litigation; our collaborators' election to pursue research, development and commercialization activities; our ability to establish and maintain relationships with collaborators with development, regulatory and commercialization expertise; our need for and ability to generate or obtain additional financing; our estimates regarding future expenses, revenues and capital requirements and the accuracy thereof; our use of cash and short-term investments; our ability to acquire, license and invest in businesses, technologies, product candidates and products; our ability to attract and retain key personnel to manage our business effectively; our ability to manage the growth of our operations, infrastructure, personnel, systems and controls; our ability to obtain and maintain adequate insurance coverage; the impact of general U.S. and foreign economic, industry, market, regulatory or political conditions, including the potential impact of Brexit; and the other risks and uncertainties identified in our periodic filings filed with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2017.
For more information about Intercept, please contact:
Mark Vignola
investors@interceptpharma.com
Christopher Frates
media@interceptpharma.com
Intercept Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
Year Ended
Product revenue, net $ 52,874 $ 37,242 $ 177,782 $ 129,175
Licensing revenue 406 445 2,022 1,781
Total revenue 53,280 37,687 179,804 130,956
Operating expenses:
Cost of sales 1,007 823 2,519 1,371
Selling, general and administrative 70,971 84,335 255,474 273,698
Research and development 63,273 57,498 207,301 191,499
Total operating expenses 135,251 142,656 465,294 466,568
Operating loss (81,971) (104,969) (285,490) (335,612)
Interest expense (7,754) (7,431) (30,523) (29,271)
Other income, net 1,720 1,128 6,771 4,516
(6,034) (6,303) (23,752) (24,755)
Net loss $ (88,005) $ (111,272) $ (309,242) $ (360,367)
Net loss per common and potential common share:
Basic and diluted $ (2.97) $ (4.43) $ (10.86) $ (14.38)
Weighted average common and potential common
Basic and diluted 29,674 25,146 28,464 25,054
Condensed Consolidated Balance Sheet Information
(In thousands)
December 31, December 31,
Cash, cash equivalents and investment securities $ 436,160 $ 414,917
Total assets $ 509,167 $ 484,347
Deferred revenue, total $ 2,432 $ 4,454
Total liabilities (1) $ 490,037 $ 467,961
Stockholders' equity $ 19,130 $ 16,386
(1) Includes $371.2 million and $355.7 million related to the Convertible Notes as of December 31, 2018 and 2017, respectively. Intercept separately accounts for the debt and equity components of the Convertible Notes. The aggregate outstanding principal amount of the Convertible Notes was $460.0 million as of December 31, 2018 and 2017.
Reconciliation of Non-GAAP Adjusted Operating Expenses to Total Operating Expenses
December 31, Year Ended
Total operating expenses $ 135,251 $ 142,656 $ 465,294 $ 466,568
Adjustments:
Stock-based compensation 11,499 15,384 49,914 56,968
Depreciation 1,031 1,345 4,582 4,601
Non-GAAP adjusted operating expenses $ 122,721 $ 125,927 $ 410,798 $ 404,999
Source: Intercept Pharmaceuticals, Inc.
Privacy Shield Policy
10 Hudson Yards, 37th Floor | New York, NY 10001 | T: 844-782-ICPT
© 2020 Intercept Pharmaceuticals, Inc.


Arconic said on Friday it would split into two companies and slashed its quarterly dividend by two-thirds, just weeks after the U.S. aluminum products maker spurned a buyout offer from Apollo Global Management.
The company, formed following a split of Aloca Corp in 2016, plans to spin off one of its core divisions later.
Arconic has been under pressure from its biggest shareholder Elliott Management Corp to sell itself and Apollo's offer last month could have valued the company at about $17 billion.
However, potential legal liabilities from its smaller building and construction systems unit likely put a question mark on the valuation.
The unit had supplied the Reynobond PE panels used in the cladding of the Grenfell Tower apartment complex in London, England, where more than 70 people were killed in a 2017 blaze.
"After a rigorous and comprehensive process…the board sees more shareholder value creation through a restructuring of the company," Chairman John Plant said in a statement, after Arconic's fourth-quarter profit beat analysts' estimates.
Plant on Wednesday assumed the role of chief executive officer in a surprise move, replacing General Electric Co veteran Chip Blankenship who was at the helm for just over a year.
Arconic said the unit, which makes parts for aircraft and power generation equipment, will now be called engineered products and forgings. The business, currently its biggest, clocked $6.32 billion in 2018 sales, a 6.3 percent jump.
Global rolled products, its second division which makes sheet and plates products for the aviation and automotive industries, reported a 12.1 percent jump in sales to $5.60 billion.
Arconic did not specify which division it intends to spin off and when but said it will consider the sale of businesses that do not fit into either of the divisions.
The company said it expects to cut quarterly dividend to 2 cents per share from 6 cents, with a target to reduce operating costs by about $200 million on an annual run-rate basis.
Arconic shares fell nearly 3.2 percent to $17.12 on Friday, after rising as much as 2.6 percent in early trading.


Image Title: Office Table Round Small Attractive Co Regarding In Desk Decorations 16. Post Title: Round Office Desk. Filename: office-table-round-small-attractive-co-regarding-in-desk-decorations-16.jpg. Image Dimension: 875 x 375 pixels. Images Format: jpg/jpeg. Publisher/Author: Ulices Dicki. Uploaded Date: Friday - October 12th. 2018 04:57:24 AM. Category: Design. Image Source: home-designing.com. Pin By Good Furniture On Table Pinterest Round Office In Desk Designs 7. Round Office Table Elegant Conference Desks Ikea For Desk Inspirations 10. Half Round Office Desk At Rs 12000 Piece Tables ID With Plan 15. China Round Desk Manufacturers And Suppliers On Throughout Office Design 3. China Modern Round Office Workstation 3 Person Intended For Desk Prepare 9. Round Office Mobilier De Bureau Gen Ve USM Vitra Wilkhahn Intended For Desk Designs 11. Commercial Office Furniture Modern Workstations Partition Within Round Desk Plans 1. Second Life Marketplace Circular Desk Office Meeting Room Throughout Round Designs 5. Design Office Round Wood Desks Click To Enlarge 60 Pertaining Desk Remodel 18. Half Round Desk Furniture Office Circle With Idea 6.


"We are thrilled to welcome Fujitsu Client Computing to work alongside our distinguished Contributor members Montblanc and Samsung," said Masahiko Yamada, DSC chairman, and president and CEO of Wacom. "Now is the time to join the Digital Stationery Consortium. Our working groups will enable DSC members to shape how digital ink innovations become part of a larger digital stationery market."
As part of the DSC, Fujitsu Client Computing Limited, known for its high-quality, innovative and reliable Fujitsu branded PC portfolio, will work to establish digital ink as universal, open and smart content format based on WILLTM: "We are looking forward to working alongside Wacom, Montblanc, Samsung and other members of the DSC to create ever-increasing array of digital stationery experiences," said Hiroyasu Takeda, executive vice president, Fujitsu Client Computing Limited.


Do you enjoy touring beautiful gardens? If the answer is yes, be sure to join Maplewood Garden Club on Monday, October 1, at 7:30 pm at Maplewood Memorial Library, when landscape designer Jana Milbocker takes us on a virtual tour of some of the best public gardens and speciality nurseries in the Northeast. During Jana's presentation you will enjoy lovely photographs and learn about each garden's highlights, history, and amenities, as well as the best time to visit. In addition to creating unique and personal gardens for clients, Jana Milbocker is the author of "The Garden Tourist: 120 Destination Gardens and Nurseries in the Northeast." Her presentation follows a short business meeting and is free and open to all.
Oct 1 / 7:30 p.m.


What is email marketing? Basically the use of email to promote products and/or services. But a better email marketing definition is the use of email to develop relationships with potential customers and/or clients. Email marketing is one segment of internet marketing, which encompasses online marketing via websites, social media, blogs, etc. It is essentially the same as direct mail except that instead of sending mail through the postal service, messages are sent electronically via email.
Which email marketing software is best?
Email marketing is one of the most cost-effective marketing tools. It is easy to manage, gives you full control and allows you to establish direct contact with your customers. For more on this topic, see our guide on why you should start building your email list right away.
While you can use OptinMonster to easily get more email subscribers, the actual email delivery part comes down to your email marketing service provider.
If you aren't careful, then you might end up paying a lot more money for fewer features and terrible deliverability (which causes you to lose even more money).
What is the best mass email software?
Hence, it's not a surprise that email leads the marketing tools used by small businesses with 54%. It's followed by tools such as the website and social media with 51% and 48%, respectively, as per Blue Corona. Furthermore, not only is 26% of SMBs are investing on email marketing due to proven effectiveness of this marketing strategy, but it also receives the biggest percentage of SMB's marketing budget by up to 15%.
As an owner of a startup or small business, you may have a mail-merge spreadsheet as your version of an email marketing system. Since growth is crucial, your marketing demands grow as well. You will soon find yourself drowned in chaotic emails and overwhelmed with unsubscribe lists.
If the budget is one of your main concerns, there are actually plenty of email marketing software programs you can use for free. They go beyond offering a free trial as they actually have plans that you can use without time limit at no cost. Meanwhile, you may also check out this article on how much does email marketing automation software cost to understand its pricing tiers.
One of the first questions new (and even experienced) marketers often ask is: "What's the best autoresponder service or email marketing tool?" Autoresponders and email marketing tools are some of the most important parts of your business. You use it to follow-up with customers. To keep people coming back to your site. To build loyalty. To make sales. Yet the answer is often not so clear-cut. Do you want the highest deliverability possible? Do you want to import offline contacts? Do you want to integrate your list management with a shopping cart? Do you want to spend $20 a month or $500 a month? The answer to these questions all yield very different answers. Here are the top 10 autoresponder tools on the market, along with who they're for and what they're capable of.
What is the best free email marketing service?
Why? Because with an email marketing, you have complete control. Not only do you own your list, but you don't have to rely on Google's ever-changing search engine algorithms for website traffic or Facebook's pay-to-play advertising model. If you want to grow and nurture your business, email marketing is the way to go.
If you don't know how to start an online newsletter or aren't sure why you need a list, read on. We're going to review five of the best free email marketing services, and why you need to start using one.
It might be time to try out a more professional email tool. But wait, before you cry out 'professional = expensive', there are actually a bunch of free email marketing services that can do the job well. No more spam surprises and no more embarrassing personal data breaches.
Which email marketing tool has the best and most powerful a be testing features let's find out hello I'm Shane black from active growth and today I'm looking at these email marketing tools and specifically I'm looking at the a/b testing features why because a B testing is a hugely powerful feature if you have an email marketing system and you have a convenient easy-to-use and powerful a B testing tool in there and you use it all the time that will have a greater impact on your bottom line than possibly any other single feature in one of these tools that's why today I'm gonna take a closer look at that so these are the tools we're looking at these are simply some of the most popular in our marketing tools I keep getting asked about.
So a good way to do this is to define a goal so you can say I want this to end when yeah let's say 300 people have met a goal and the goal would be something so maybe they register for a webinar or maybe they buy a product and in most cases this would happen through tags so you can specify conditions and you can really specify all kinds of stuff but in most cases you would have something like a customer tag right they've bought something so we have a bunch of customer tags this is an application I'm actually using for thrive themes so I can basically say when someone becomes a customer they make a purchase and we have a system that adds this tag to them that's the goal right.
I can say I want this split to run until 300 people have reached this goal and once 300 people have reached this goal we're going to look at which of the two paths has been more effective so which of them has had a bit a larger conversion rate related to this goal and we're gonna send the rest of people coming through this automation down the path that was more effective so this is great this is great for many reasons first of all because you can so freely define the goal it can be anything from just getting people to open your emails or getting people to click on links or getting people to buy stuff whatever your goals you can set them here and the other thing is that now of course what we can do is we can say okay send an email so we can do something like this right we're recipie we're sending people different emails and over time as people come through this automation we find out which one works better but we can send people down to completely different paths right we can use all of that we can send emails and messages we can have different intervals right different waiting periods we can have different segmentations we can try you know a series where we send them a short email every day versus a series where we sent them longer emails less frequently we can try like you know hard selling promotion versus storytelling whatever you want to do you can build two completely separate paths here.
Find out which one works best so this is really powerful and the implementation is great I think the application is very straightforward you can easily imagine how this works and there's this automation aspect to it so just like with the broadcast team as you set this up once you just leave it running and you know that you know once the goal has been completed by enough people everybody who enters this automation will go down the more effective path one downside I have to mention for active campaign is that in our case to use this to track something like a purchase goal so like I showed you know we basically split and see which path leads to more customers but we did have to build a custom integration for that so there are not many first-party integrations like codeless integrations between active campaign and things like payment providers or membership tools or e-commerce tools where they're slowly starting to build that but that is one downside that I think is significant right it would be much better if you could just directly hook into your PayPal or your stripe or whatever.
Get purchase data and even better would be revenue data and you know be able to test for revenue that would be perfect and that is currently not possible unless you're using like one of their very few deep integration type integrations so that is a downside to get really the most out of this you'll probably have to set up as a peer integration or get some custom coding to send you to know the right tags over to active campaign whenever someone makes a purchase but overall this is some impressive a be testing functionality in active campaign okay candidate number two is autopilot so we have some way let's do let's say someone submits a form they enter this journey and they enter an automation so and we want to do a be testing so we have an action here called an a/b split we can say when they submit the form they go into this a B split and then we have a and B so we send people down different paths.
We can set the split amount right so we can do a 50/50 or a different kind of split so then we'd have our usual actions so let's say we send an email on path a and we send a different email on path B and we can get you to know we can see this quite visually here a goes here because here now so far so good the problem here is that unlike with active campaign we can't tie this directly to a conversion goal and we can't automate this so we do have the same kind of thing where I can choose to completely separate journeys to send people down using all of the usual actions so that's that's great but if we actually look at how its explained in their knowledge base the example they gave of how to do an a/b split test is is actually this here where they basically say you send you're you send people down this actually to splits here and test these two newsletters and the idea is that you sent the rest of your traffic down the delay alright there you have them wait and before this wait is over you're supposed to go and manually check which one of these perform better.
Then copy that email put it in here okay so they're basically saying you know send the email put I guess you know put a reminder on your phone or something that okay before this one day delay or two day delay or whatever it is is up I gotta go and check these two emails you know copy whichever one was the better one and then put it in here into this path which we have a 1090 split so most of the people will then be going down here so that this is basically the problem with the autopilot integration so theoretically it would have this power of being able to give you two totally separate paths and being able to test out the paths but because you basically have to manually then look at the reporting and look at you know what works it's not you know taking action on what you learn from the from the test results isn't easy so you can either follow their advice here this would be for basically a broadcast right you send one email and then make sure that most of the people get the email that performed better I think this is not an elegant solution I mean it's it's it's better than nothing and there's definitely some worse solutions as we'll see but it's not great and what you can also do is if you do create two totally separate paths which like I said I think this is one of you know one of the great things is you can do more than just test different emails you can test totally different journeys but it will make it different difficult to then take action on that because you'll have to go.
This is important because for the a/b testing well what I just showed you it so they have an a/b testing feature that's a bit inconvenient for one-off emails and it's even more inconvenient really for you know ongoing complex follow-up journeys so I feel like with autopilot it really is you know okay they have an a/b testing feature it but it misses the mark you know this could be so good if it were combined with goals but it's not so this is I would consider this a near-miss okay next up we have an old-school email marketing tool Aweber from from looking at aweber marketing stuff we can see that they do talk about you know getting higher email open rates by split testing subject lines for example and there are some old videos about how to do it but then if you try and find the current instructions of how to do it this is the closest like KITT it seems that there used to be a split testing feature.
Aweber but there currently is not so in their campaigns I couldn't find any way to do it here in their message you know where you create broadcast messages or emails I couldn't find a way to do it either so it seems that it's simply not possible so here the answer is pretty short for Aweber there is no a/b testing for broadcast emails no a/b testing for follow-up campaigns that's it features doesn't exist or at least doesn't exist anymore alright next up we have convertkit convertkit is a new ish kid on the block or at least it's become popular recently so let's see what it's got up its sleeve when we create a broadcast email in convertkit we first choose who receives the email and then we go to the next step so here similarly you can choose which list you can add segmentation criteria that kind of thing and here so here we have subject line 1 and right away we have this feature here for an a/b test and I got a error message that I'm not sure why but anyway this would be subject line 2 probably because the email was empty right but anyway you could test subject lines you can't test content but I think this is commendable because it's it's a very simple straightforward feature you can only test two versions you can only test subject lines and that's it now, of course, it can be really powerful if you can also test your email content but this is like the 80/20 you know the most convenient thing to test is the subject line something you can do every time you send an email.
It's kind of the simplest thing that you get the highest return on as soon as you go into testing different email content with different links and so on things get complicated but you might not get you know significantly better results for how much more time you'd have to spend on this so I think this is actually good you know I obviously I prefer a more powerful feature but just having a simple thing you know do this right a be test liked has two versions of a subject line that's it just do this every time you send an email you get good results from that so than on the next step here we can see that each variation will be sent to 50% of subscribers then the we're winning variation be sent after four hours as far as I can see there's no way to edit this that's just the default setting they should make this editable and simply because on a smaller list this will not work as I said before I prefer to use a 30 30 40 split to basically get a more reliable results.
You know maybe four hours isn't enough for the four hours is reasonable I think but yeah I would like to be able to change this so again I think they went for you know you don't think about it just do this for you which can be good I would prefer a bit more control here though now what about in follow-up sequences that's a little complicated in convertkit because there are two aspects to this we have sequences which are basically linear sequences of emails and we have automation which is this automation flows that we're used to from other tools as well so let's have a look at one of our test flows here so what we can do is we have a trigger someone gets into this flow and then we send them a series of emails.
How did we determine which email marketing tools to include?
The emails aren't individually represented in the flow so this is a sequence of emails that someone goes through and if we look at the email sequence itself in here there are no a B testing features there's no way here to do the same thing for example with the subject line so we can't do that then so let's go back to the engagement we can also we can have conditions in the flow so we can jump to somewhere when a tag is added or removed or when a certain date is reached we can send an email sequence to add or remove text or add a delay and we can have a condition which is based on a tag or custom field but this is not like a split right so I can say okay you know does the person have this tag yes or no now theoretically it's possible to use such a conditional split and kind of try to randomly assign people you know and in Group A and Group B tags when they sign up and then you can try and run something like an a/b test on an automation using one of these conditional splits but no that is not real a/b testing I've seen that you know in some cases though and we'll get back to that in a later example actually you know sometimes this is advertised as yeah you can do a B testing right you can do it like this manual assign tags and manually check reports and stuff no that's no that just doesn't count right and so in conclusion with convertkit we have a very simple very easy to use and good a B testing feature for broadcast emails that is it's good but it's very limited.
We have no a/b testing for follow-up automation which is too bad but that's where we stand with kin kick our next email marketing tool is rip and I gotta say right away I was disappointed in the a/b testing features in drip let's look at why so in campaigns which are linear sequences of emails we have split tests we can create a split test here and we can test one of three things we can either test subject line the from name or the timing of delivery subject line will be against usually the highest the most convenient highest yield thing to test so let's choose that we choose one of our existing campaigns that the idea is you create your campaign first and you activate it and then you choose it and then you create a split test and kind of add that campaign to the split test so already if this sounds a bit convoluted it's it's become loaded so now I'm choosing an email within this campaign that I want to test.
Choose this go to the next step and then this is my first subject line and I go subject line to something else right and I can add more variations so I can test more than two variations against each other here but then from here I can start the test so and then I have a report for this specific email within this specific campaign so again if this seems confusing it's because it's confusing right it's so that I have a report about a split test that runs on a specific email in a campaign which is a series of emails that I've created before and there's also as far as I can see there's no automatic winner so the idea is I just come back here and determine which one is winning and then end the test.
Choose which one should keep running and this is just for a subject line test in one e-mail in one campaign so I'd have to do this for I have to go through this and make sure my labeling is good right so I know what the hell is going on for all the emails in my campaign I don't know this just seems unnecessarily confusing to make it more disappointing we have for broadcasts if you send out a broadcast email to your subscribers there's no a/b testing there this is simply not possible and that let's look at the automation within workflows so in a workflow like this where we have different steps and different conditions some of these steps are campaigns so this step here represents a campaign which contains multiple emails.
Within this campaign I can be testing a subject line of an email but not I can't tie it to a goal right again there's like there's no basically the a/b test is almost like it runs separately from everything else I'm doing here and it can't impact the results of the a/b test can't directly impact my workflow which kind of defeats the purpose of you know that's what you'd want from an a/b test within a workflow we can also have conditions here but just as with actually no a fork is a different thing as a bit of a strange thing but we can have conditions like what we have here right we take for a tag and we have a yes and a no path so just like in convertkit theoretically we can somehow finagle this into something like an a/b test but I don't recommend it and in fact this is like this appointment part three is that this is what they basically recommend there's a tutorial here that basically says okay you know apply different tags you know to apply your bucket a and bucket B tags to people and then use those tags to send different messages different broadcast messages and then check your analytics and then so on this is not real a/b testing this is not randomized, to begin with and if you have a bucket an in the bucket B and you're constantly running tests on the same two groups of people without further randomization the more it has to run on that the less relevant two results will become so, in summary, we can do a/b tests in drip but only two individual emails inside campaigns so inside sequences of emails.
We can place those sequences inside an automation workflow but there's no automatic winner and we can't make a flow where you know we automatically adjust the flow based on what performs better so and we can't a test broadcast emails so really this is why I said I was disappointed to look drip is in every other way drip is such like a geeky power user marketing tool you know it has such great features to do some really powerful marketing stuff but somehow on a be testing they have completely dropped the ball and I really hope that they will improve this in the future but as of right now this is pretty bad next on our list is get response get response does have an a/b testing feature and it does it when whenever you create what they call a newsletter so you created an email and in the distribution settings it's strange that it's well hidden like this but anyway you click on this and then you would turn on a be testing and so here you choose your list you create your message very similar to the first steps that we've seen in other in tools before and yeah so here's where you decide whether we want a be testing or not then you go to the next step here is where you will be creating your actual email content we have an email builder with various blocks and mobile preview.
So on so you compose your email here you go to the next step and then you have a an a/b test type to choose from so you can choose to test subject lines from fields content so you can create a different message or even use a totally different template or different delivery times which is I think great this is this is you know it's a good idea not to test these things simultaneously you want to isolate a single factor so having this as a multiple choice here is good and I really I mean I like this interface you know it it kind of walks you through in a very obvious way the only issue really is that initially it's it's so hidden the a/b test feature is hidden like that but the flow here really makes a lot of sense and then it's very convenient to do right so we have subject line one line two and we can add more and yes it's just as you'd expect when we go to the next step then we choose CBN's on this step.
Who should use this email marketing software?
We can also have some exclusions so that's again similar to other setups we've seen and then we've we have this visual representation our codes this right you can you can choose how the email will be split it seems that it's limited at 25 25 50 but I guess that's fine and then very importantly send best message automatically that's you know for me this is the point of using tests like this you can choose open rate or click rate that makes perfect sense to test and you can choose a duration so here again we could have what would I had last time something like 5 hour delay and you can be notified so this is how we create a split test so the split test is part of the email message now in get response there is now also an automation builder like this and it has basically all the typical software used to you can enter people into automations you can add steps such as moving someone to a list and you can connect the steps to each other to create workflows and what we can do here is well inside one of these we can have our message so this would be an email message right sending an email message.
We can choose what kind of message to send here including newsletters we've previously created the AP tests we've previously created so in here we can also select a be tests right we can choose to a/b test an email within this flow which is not the same as being able to split the entire flow and as far as I can see there is no feature to do a split of the entire flow but we can have messages within the flow running a/b tests and we can have those messages automatically optimized so with get response we've got a pretty good pretty user friendly a be testing feature which can apply to broadcast emails and we can also have emails inside our follow-up workflows or automations be automatically optimized that's good so we you can think of it like you can have your automatic workflow and it can get better over time get more people to open and click overtime but you can test two completely different flows against each other and you can't basically try two different flows and automatically lead people down the more effective path after a while so this is one step removed from the kind of thing you could do in active campaign but it's still pretty good this is one of the better a be testing feature sets that we've seen our next tool on the list is eye contact in eye contact when we create a message we get to choose from many of their totally overdone templates and we'll just go with the default one here and in the editor here is where we can change our email content.
We can enter a test one subject line and we can also call this you know a/b test one or something so this is what the message will be called and then in the tools here we can create a split test so we create a split test and we can duplicate the message so I would compose my message first and then say duplicate and then I can change the subject line and I can also change the content and whatever else I want and oh I should have actually switched to version P here first so here now on version B we've got test one as the subject line and version a we've got test two but it matters not we have our two test versions that we can switch between so an advantage of this feature is that we can easily test the subject line and content and it's pretty straightforward right we just use the same editor for both a disadvantage or a limitation is that we can only have two versions which I think isn't you know this isn't a huge problem I generally test just the control and want one variation anyway so then we go we can do our previewing and all this kind of stuff you get everything ready to send and then we go to prepare to send in this step is where we choose who receives our message including segmentation options as well and then here it's a bit strange I mean we have this pre checked.
The split test because we we set it up as a split test we can't uncheck it but nevermind we have our name that we can change here again and we can choose the percentage so in this case what this means if we have so if we set this to 40% as here means that 20% and 20% will get our two variations and then the rest of the list will get the winning variation interestingly the way this works is that as you can see here after you decide which version performs better so I don't choose a conversion goal here I don't choose open rate or click rate or something the idea is that I take a look at which of the you know I take a look at the reports of these messages and then I choose which one I want to send to the rest of the group so it's not as automated but it's also it's not too bad it's not like super inconvenient either so in eye-contact we have got a passable a be testing feature basically this very middling because it's fairly well put together it's not too complicated to use but it does require manual intervention and you know it's just it's just not that great it's not bad it's not that great doesn't really stand out but there it is that's what you can do in eye contact the next tool we're testing is MailChimp and surprisingly MailChimp does have AP testing features I didn't expect this because MailChimp is usually kind of basic.
Beginner oriented but take a look at this in MailChimp when we create a campaign we can create an email and here we can choose to run an a/b test so we'll call this a be test demo and let's get started then we choose who should get our a/b test and we can send to everyone or so the segmentation happens in this step here and then next up we can choose what to test so we so again it's kind of like the other way around a little bit from what we've seen before here we kind of set up the parameters of a test first before we get to the actual content now I can choose to test multiple subject lines or we can choose to do the from name or the content but as you can see it's kind of like the get response version where you can only you can choose one of these things to test and when you test one you can test the others which is a good thing that's that makes sense so let's go with subject lines as we've done in all the other examples and here we can set how many people this will be tested on again the same principle right we choose the how many the basically they're the size of the two groups that the test runs on.
Then this is the group that will get the VIN the winning variation so we set this to whatever we want and then we have by open rate click rate or even by revenue so if you've connected it to an app that tracks revenue this is great this is a great option and again I'm actually I'm surprised I didn't expect this from MailChimp right this is the kind of thing that I would have expected from a solution like drip but not from MailChimp so this is great well done MailChimp okay so we have open rate you can also do a manual selection and set the time and here we can get a summary of what this means and then we move to the next step all right so then we have our name here we enter our subject lines test1 test2 and this is a little snippet that can appear in the email preview we can test that but that's fine and here we do a bunch of another setup for what we want to track Google Analytics integration.
Things like that and then we go next here we choose some template as usual and because we've already setup our subject lines before our test setup is already done so here we just compose the email if you choose to test the content then here you basically create your content and create a version of your content to test and then go to the next step and then we're basically done so here we have an overview of what's going on and we can then choose to schedule or send the email now MailChimp has also introduced what they call automations and these automations are in this kind of way calculate the Aweber ones basically series of steps so linear series of steps where you send email messages and you can have triggers you can have triggers other than just wait a certain amount of time you can wait until someone does a certain action clicks on a certain link you can connect it to e-commerce and trigger things by what people buy but it's not the same kind of it's not level of sophistication that you have in a proper workflow builder or automation builder like we see in active campaign or drip.
Also with these messages you design here in these automations there's no a/b testing feature for the follow-up or for the automations so with MailChimp we have a good a be testing system for broadcast emails and in fact a very good one because you can even connect it to your shopping cart and test for revenue that is so cool I want that in all of the tools and you have no a be testing for your automations or follow-up campaigns but these campaigns are very basic, to begin with so you know if you want to build sophisticated workflows you're not looking at MailChimp anyway the next tool on the list is mailer light and it made a light we can create a campaign we can create a new email and right here we can choose an a/b split test we could use to test either the email subject the from name or the email content and once again we'll go with subject so we have test 1 test 2 and then we go into the next step which is selecting the content what I what I really like here is you can also get the templates and all that but you can also just do a text editor and I'm all about those texts only emails so here we compose our email and remember we've already set the two test subject lines so here's just about the content then we go to the next step here we define who gets our email.
Create professional email campaigns that bring customers to your door.
We can segment our subscribers into different groups and choose which groups get the email and then we go to the next step and here is where we get to choose the split so here at the last step is where we decide how to run the test and what to do with it and once again we have a visual representation of this – I think it's great of how the split will go and we can choose to select the winner by open rate or click rate and we can set a delay so it's very familiar actually right it's very familiar with the other systems we've seen but that's it here we set up our test and then we set the scheduling or send right away so that is for sending a campaign which would be a broadcast email to your whole list or group on your list made a light also has automation so you can create these flows that can include email messages delays and conditions such as did someone interact with the previous email or did someone is someone in a specific group or not.
You can define various actions and things but in these flows there is no a/b testing so I made a light this is starting to look like a familiar story we can do a/b testing for broadcast emails fairly good feature set there but no a/b testing in our follow-up campaigns so again it's kind of a middling solution but it's certainly better than having no a/b testing at all next up is another interesting tool Martic here when we've created an email we can go in and choose to add an a/b test to the email and this takes us through all the other steps so we can choose a separate template we can change the subject line I'm going to do that and we can also change this would be email test version or something for internal labeling and here we have to choose how many people will get this and this is the total split so if I if I say 25% here that means that the original that I created this a B test from will get 75% of the traffic and then the winning criteria we can to read rate so that we open rate click-through form submissions doesn't really make sense on an email very much or download rate if you use mortix asset delivery feature so let's let's keep it with this with this setup so we could just save this and then it's a subject line test or we can go into the email builder and make changes so here if we go back into emails we have this symbol that says it has an a/b test running and down here there are variants so here we can see and I can activate this as well so this would then start the test.
Also I have to say it like the whole set up of the emails and the AP test variations and the sending it sounds quite convoluted in this tool now inside a campaign inside an automation building a campaign we can we can build flows workflows like this as well so let's open the Builder here so here in a flow like this we can have we can have triggers we can have sending options we can have conditions and we can choose emails to send here we can choose to send an email that has an a/b test running that means if we have an automation like this where people are coming in and going through this continuously then there it makes sense there I can get some use out of it because I can let's say let this run for a week or so.
Then check which email is performing better and then make sure that that email is going to be sent to everyone who comes through this automation in the future so in summary with more tech we have a fairly complicated not that useful a be testing feature for broadcasts and we can insert a be test in our flows but again we can't test totally separate flows against each other and overall my main problem here is that it's just not nice to use but it's quite complicated you have these you have the email that has variants but each variant has like its own interface and it's not quite shortened then you have to go to campaigns to actually send the email it's just it's all a bit complicated and this is it's the kind of thing where you know I can see this as one of these features that it's there but you'll end up not using it very often because yeah it's just thought you know it's not user friendly enough so that is more tech now our next two tools are really quick because send in blue has no a be testing features for either broadcasts or follow-ups and the same is true for sandy so sandy comes up a lot because the very cheap solution that you self host.
Use with Amazon SES and same here there's just no a/b testing features whatsoever inside so the last two tools on our list were pretty easy to get a grip on so overall as you can see that there's basically three let's say broad categories here number one is actually active campaign in its own category because it has just badass a be testing features both for your broadcast and for your you know conditional follow-up automation stuff it's basically anything you want to test you can do the only thing that's missing is testing for revenue then we have several tools like get response and MailChimp and convertkit that have some AV testing features you can do some a/b testing often you can just a be test broadcasts but you can test everything.
That's great I would say that anything that has at least some a/b testing features or at least you can test some subject lines and so on that would be a minimum for me to even consider using a tool and then we have a third category of tools where there are no a/b testing feature at all or the a/b testing features are so limited or so complicated so annoying to use that they might as well not exist and I would put like you know more tick and drip or both solutions where okay they both have a be testing but mmm are you gonna use it are you gonna be happy with it it's questionable now to get a better overview of all this you can check if you're watching this on youtube check the link in the description otherwise just scroll down on the blog post.
There's a comparison table and some written summaries of this and of course I would love to know if you have other experiences if you have other tools that you think I should look at or if you have any questions about how to make use of this kind of stuff just leave a comment below and I'm really looking forward to hearing your feedback so check out the blog post that goes with this pretty important information there and a much easier way to get an overview over you know and make a decision basically based on the comparison table I've put together for you and that's all I'm shaving a lot from active growth thank you for watching and I'll catch you in the next one.
Hi Earn second salary from home – even $30k/month.


I'm in love with all things apple right now, so when LorAnn Oils asked if I was interested in trying out some of their specialty flavors, I was all for it! I got to try out their Green Apple and Butter Rum super strength flavors as well as their new Cinnamon Spice Bakery Emulsion. I thought that the combo of green apple and cinnamon spice was just perfect in these Green Apple High Hat Cupcakes!
First off, don't be scared – I totally used a box mix. However, you'd never know from the extra flavor that I added! And I chopped up some green apple and added it to the cupcake mix.
Once the cupcakes were baked, it was time to pile them high with lots of frosting! The trick to high hat cupcakes is having thick frosting and then freezing them before dipping them.
I used candy melts that I colored with green food coloring oil (don't use water based colors) and added just two drops of the super strength apple flavor. That name doesn't lie! Go easy with it. It's SUPER flavorful!
Once the shells were hard, it was time to drizzle on some caramel and hand them out to my party guests!These were quite a bit easier on the teeth and so delicious to eat!
Please check out all the other Bloggers from #OBC14 to see what they have made using LorAnn products.
With the leftover Green Apple Candy, make some bark or some lollipops. Simply place parchment paper on a cookie sheet and spread it out. Refrigerate for 10 minutes then break apart. If you're making lollipops, follow THESE INSTRUCTIONS.
Prepare the cake mix as instructed adding in the chopped apples and LorAnn Cinnamon Spice Emulsion. Bake and cool as directed.
Place the frosting into a mixer and gradually add in the powdered sugar. It will get very thick. You want the frosting to hold a fork upright in the frosting.
Pipe a large amount of frosting on to the cupcakes and then place in the freezer for at least an hour. I left mine in overnight.
Melt the candy melts of CandyQuik according to the instructions. I like to place my melts into a tall coffee mug and heat in the microwave at 70% power for 1 minute. Do NOT over heat the melts. They will burn. It can take several minutes for the candy to melt, do not rush it. The mug should never be hot in your hands, just warm. If the candy is melted, but seems thick and doesn't drizzle off the spoon, add some coconut oil or shortening to thin it out. Start with a teaspoon, but don't add much more than a tablespoon. Very carefully add in the Apple Super Flavor and stir to combine. Remember, you can always add more, but you can't take it out.
Remove the cupcakes from the freezer and dip them straight down into the mug being careful to just cover the frosting. Shake off the excess and place on a tray.
Once all of the cupcakes are done, leave them at room temperature until ready to serve.
Top with Caramel Sauce just before serving!
For more Awesome Cupcake Recipes, check these out!


Q. Why do you feel Gospel is received so well in Europe ?
A. Afroamerican music period is well received here in the old world. There is many reasons for it. I love it because it's real.
Q. When and how did you meet Rev. Johnny Thompson ?
A. I met Johnny back in 1968. He was the piano player for the legendary Stars Of Faith Of Black Nativity and I was 22 years old - their Road Manager. During a few off days we spent together in Brussels (1969) Johnny gave me a brochure of his own group - which he founded 1965 The Johnny Thompson Singers. The plan to bring them over to Europe did not get out of my head. 1971 we did it. The Johnny Thompson Singers since then toured the world over and I cannot even count the tours over 60) and concerts (over 2000) anymore..........we are still together and never ever signed a contract. All our agreements were, are and will be one hundred percent mutual.
Q. What impact do you feel gospel has made on music in the past and present?
A. A strong one indeed. Almost all commercial music of today is based on Gospel somehow. If it isn't the music pattern it is the performing artist and if it isn't the artist it may be the sound, the beat, the feeling. Gospel is the base of the today's r&b, the "holy" brother of the blues and after all the heart of jazz.
Q. What type of groups were on the European scene first with gospel music, choirs, quartets?
A. I guess the very first were "The Fisk Jubilee Singers". They came to Europe back in 1877 to perform for raise money to build the Fisk University. But the ones I do remember are Mahalia Jackson, The Stars Of Faith, Alex Bradford, Marion Williams, The Patterson Singers, Bishop Kelly, The Golden Gate Quartet, Sally Martin, Bessie Griffin.
Q. What other Gospel groups have you booked in Europe?
A. Beside The Johnny Thompson Singers I brought Rev Fulton Gospel Singers Ensemble (1974), Alex Bradford/Alberta Carter (1974), Marion Williams (1974), The Pennsylvania District Choir (1976), Barbara Purdy/Gloria Roberts (1981), Silvia Wright/Lee Cochran (1991), The Davi Winslow Gospel choral (1992), The Olde Tyme Gospel Singers (1998, 1999, 2000), Brenda Waters (1999) across the water but I also booked (still do) a few Afroamerican Gospel artists travelling or living in Europe, such as The Golden Gate Quartet, The Stars Of Faith, Jerome Van Jones, JoAnn Pickens, Hedreich Nichols and Richard Broadnax.
Q. If you compare Gospel music to taday and in the earlier days how does it differ?
A. More quantity, less quality.
Q. Are they gospel groups from Europe? How do they differ from USA groups?
A. Yes there are many many European Gospel artists. I don't follow this scene very close but I do know that some of them are very successful. Nobody can stop the worldwide gospel movement to mention one positive aspect of all those singers, bands, groups, choirs.
Q. Who generally attends a Gospel concert, young or older adults?
Q. In what countries have you produced Gospel Concerts?
A. Let me think. I give it to you in alphabetical order, and you will count them, okay? Austria, Belaruse, Belgium, Bulgaria, Denmark, Croatia, Czechoslovakia, Czeck Republic, Egypt, Eire, England, Estonia, Finland, France, Germany, Greece, Holland, Hungary, Iceland , Israel, Italy, Latvia, Liechtenstein, Norway, Poland, Portugal, Russia, Soviet Union, Spain, Sweden, Switzerland, Yugoslavia.
Q. Is there a place where you would like to book The Johnny Thompson Singers?
A. Of course. My dream is China, Japan, Australia, New Zealand and all over Africa........and I am working on it every day.
Q. What is themost memorable concert you expeienced with the Johnny Thompson Singers?
A. There are quiet a few. The very first one in Berlin (1971), because I booked the group before I even heard them. I just knew Johnny, that was good enough for me. And I wasn't wrong either. Then 1972 when the JTS were the first Gospel group performing at Montreux Jazz Festival, 1984 for the first time at the Opera house in Zurich, 1989 at the Opera house in Cairo and last but not least the first time with a big orchestra during the first "Gospel Christmas" tour in 1996.
Q. I understand that Rev. Johnny Thompson is also a playwrigt?
A. Yes and a very good one too! "Master I Want To Live", his first Gospel-play is in Europe every year since 1997 and we will present another one this year. "Little Dark Baby" a Christmas play. "The Gospelers" is also in the back of my mind, but concrete plans will take a while........And you know, he wrote ten plays. One of them (a secular one) traveled all over the USA and even won a journalist prize in London werer they played several weeks. "Little Willy Junior's Resurrection I am talking about.
Q. What's the next Gospel highlights?
A. Okay, the ones I consider: On June 24th, 2000 is a big celebration for the 35th anniversary of The Johnny Thompson Singers. This will be held in Philadelphia USA and 1500 guests will be there.......including me of course.Before that "Master I Want To Live" will be in Zurich for one month, the Thompson Singers will be guests of a few European Jazz Festivals and I am also working on the tour for the fall with the Gospel Christmas concerts (this year with the chamber orchestra of Dvorak Collegium) and "Little Dark Baby" the Christmas Gospel Play... and for 2001 I would like to organize concerts with The Thompson Singers and Jessye Norman.
Q. What is Rev. Thompson's significant approach to Gospel music that makes him different from other groups?
A. Johnny Thompson is a natural born talent, has an extremely good feeling for rhythm, sound and words, is a hard worker, a true believer and a strong leader. His sound never really changed since his first hit (for Shirley Caesar) "Stranger On The Road" it is just perfected, fuller and adjusted to the today's world.
Q. The Johnny Thompson Singers are travelling for a few weeks in Europe. Is this good enough for a living?
A. Yes and no, but I can only speak for myself and talk about the ten thousand little things me and Johnny are doing every day. As I told you, I am working with a hand full of Afroamerican artist living in Europe, I handle a small publishing company and I am also partner in a rather busy concert promoting company here in Switzerland. Not to mention the "job" as a husband of a young wife (Rosie) and father of two "little" girls. Nadine is twelve years old, Xenia only six.Johnny's days are even more hectic. He is pastoring The First Apostle Fire Baptized Church in Coatesville, Pennsylvania, he's rehearsing the Johnny Thompson Singers, the different casts for the plays, he's involved in Dorsey's Gospel Convention and in Cleveland's too. Besides he is writing, composing, arranging his music, preparing his preachings, organizing his church events and managing his record label "Superb Records".
Q. Let's talk about recordings.
A. That's a story by itself. We produced more than three dozen albums and CD's. We won prizes, sold pretty big numbers of copies here in Europe (especially the Christmas CD's recorded with The English Chamber Orchestra) but for some reason (don't ask me why) never hit the US market the way it should.
Q. But Johnny Thompson wrote so many songs!
A. Yes, big hits too. One of them "Shake The Devil Off" was in the charts for almost a year. Or do you remember: "Stranger On The Road", "If I Perish", "Hold Out", "Hallelujah This Is The Highest Praise", "The Creation", "Get Up My Brother", "There Must Be A Reason", "Happy On My Way" just to mention a few.
Q. What quality in Rev. Thompson do you admire the most?
A. His talent, his sense of humor and the always positive vibrations coming from him.
Q. That's all you can say?
A. No, of course not. I could write a book and one of these days I may even do that.
Q. What is your favorite anectote in connection with Gospel music?
Q. Is there a negative aspect to Gospel music?
A. If there is, it's too late to think about it after being involved for three decades, don't you think?
Q. What advice would you offer to someone just getting started in the business of singing gospel?


At Eatery at the Grant House, we place a high value on locally-grown ingredients and farm to table freshness. We have access to nearby farms and fresh seafood is just an hour away. Because of this, we're able to bring the freshest ingredients to our kitchen, and then to your plate. We're a farm to table restaurant and we take that very seriously.
Starting at 5:45pm, Sunday's are for suppers so we're gathering around our communal table to break bread and swap stories every other Sunday at The Eatery at The Grant House.


Bedroom Cabinets Design Best Of Cabinet Pertaining To Remodel 43 is one of pictures thet are related with the picture before in the collection gallery. If you would like to see the Bedroom Cabinets Design Best Of Cabinet Pertaining To Remodel 43 in High Resolution [HD Resolution] version, please press the right click on picures/image then choose "Save as Image" option, and done. You will get Bedroom Cabinets Design Best Of Cabinet Pertaining To Remodel 43 pictures that you want. The exactly dimension of Bedroom Cabinets Design Best Of Cabinet Pertaining To Remodel 43 was 1024x734 pixels. You can also look for some pictures by collection on below this picture. Find the other picture or article about Bedroom Cabinet here. We hope it can help you to get information of the picture.


After launching the upgraded version of the Galaxy A series, Samsung has recently launched the upgraded 2016 edition of the Galaxy J series, & in this post we are going to discuss about the Galaxy J7, the device comes out with lot of improvements which includes design, hardware, O.S, battery, etc, but also has some flaws. The Galaxy J7 also features the muck talked about S bike mode.Samsung will be putting the Galaxy J7 against the likes of OnePlus X, Moto X Play, Xiaomi Mi5, Lenovo K4 Note, etc, currently, the device is being sold in India via Flipkart at a price of Rs 15,990, so in this regard, we are going to the mention the top 7 things which you must know about the new Galaxy J7 2016.
The device sports the same 5.5 inch Super AMOLED display, offering a resolution of (1280×720 p), which is kind of setback because now all the devices in this mid-range segment feature a full HD display. The display also misses out Gorilla Glass protection. Coming to the screen quality, the display looks quite vivid, and also offers good viewing angles.
Under the hood, the device packs a new upgraded Exynos 7870 octa-core processor coupled with 2 gigs of RAM, for gaming, the device gets an ARM Mali-T830 GPU, so even if you do heavy multitasking or gaming you'll get a smooth experience.
The Galaxy J7 2015 had a Mali-T720 GPU, whereas, the 2016 edition packs a more powerful Mali-T830 GPU, so games like Nova 3, Modern Combat 5, Riptide GP2, Asphalt 8, NFS, etc can be played on this device without facing any kind of shutters or frame drops. Another good thing is that the device doesn't heat up, even if you do gaming for a long duration.
The device misses out the Ambient light sensor, as a result, you have to manually adjust the brightness of the device, other than the ambient light sensor, it all misses out important sensors like Magnetometer, Gyroscope, etc, which is quite unacceptable for a device having a price point of Rs 16K.
At the back, there is a large 3300 mAh battery, which offers a usage of 1-2 days for a moderate user, another feature which Samsung has added in the Galaxy J series of 2016 edition is the ultra-power saving mode, which on being turned converts the display into a black & white display, which can be a very helpful feature when you are outdoor, and the battery is quite low, so the ultra-saving mode feature will help the device last for 4-5 hours.
At the rear, the device gets a 13 MP camera, whereas, and the front gets a 5 MP camera, both the front & rear camera is also getting supported by a LED flash, coming to the camera quality, both the camera takes sharp crisp images with good amount of detailing and color accuracy, images taken in low-lighting conditions also comes out with decent amount of detailing.
The Galaxy J7 2016 edition comes out with lot of improvements, but still misses out some important features like full HD display, metallic body, fingerprint sensor, which are now easily available on other smartphones in this price segment, so if you want a Samsung smartphone with good gaming & camera performance then, the Galaxy J7 should be your pick, but if you want a smartphone loaded with features under Rs 16K, then you should give a look at other smartphones.
Nice list. This will help someone who is planning to buy this phone.


Discussion in 'Hardware' started by segoncziekg, Jan 22, 2006.
I have received a 17" Flat Screen LCD Monitor, how to clean it, handle it, does it need special care?
There exist special cleaners for LCD screens, which takes all the risk out of product selection.
Do NOT use any sort of paper towel to clean the screen, only soft cloths. Paper will scratch the screen, hard as that is to believe.
Stay clear of any "cleaners" not formulated to clean LCD screens..Go to your local or online Bestbuy and order some..It's cheap and worry free..
I like to shop at Best Buy. Thanks for the suggestion.
I never clean my monitor. My big, fat, long haired cat walks in front of my screen 'bout 10 times a day so it's never dirty!
I must borrow my son's cat to do the same for me.


text:
Mets Bats, Not Collins Decision, Reason For Game 5 Loss
Brady Farkas
Brady Farkas Published: November 2, 2015
Terry Collins is going to catch a lot of heat for sending Matt Harvey back out for the ninth inning in Game 5 of the World Series.
Harvey had been dominant for eight innings but was over 100 pitches. Closer Jeurys Familia was ready in the bullpen.
Harvey was told he was done. He fought to stay in and he won.
Collins will be blamed for the World Series loss, almost like Grady Little was blamed for leaving Pedro Martinez in for one inning too long in Game 7 of the 2003 ALCS.
But it's not Terry Collins' fault. It's not Matt Harvey's fault.
World Series - Kansas City Royals v New York Mets - Game Five
The Mets offense is the real reason for the Game 5 loss (Getty Images).
It's the Mets offense. The Mets offense that couldn't capitalize. The Mets offense that was 0-5 with runners in scoring position and left six men on base.
It was the Mets offense that let Edinson Volquez off the hook after he walked the leadoff man in the second inning.
It was the Mets offense that let Volquez get away with a one out walk in the fourth. Volquez walked the leadoff guy in the fifth, also, and the Mets came away with nothing.
And then, the most egregious performance of them all came in the bottom of the sixth, when Volquez walked the leadoff man for the third time. He loaded the bases with nobody out. And the best the Mets could do was one run on a sacrifice fly.
Bottom line: The Mets failed to capitalize on OFFENSE. The offense put Matt Harvey and Terry Collins in that position.
Collins and Harvey will be remembered, but it's the Mets offense that couldn't close it out.
Filed Under: Mets, mlb, Royals
Categories: Buster Olney, MLB, National Sports, NY Mets

redpajama_set_name: RedPajamaCommonCrawl


Kuroshitsuji shiver 2 OP Chord by: RYD86 Intro: G A A# G F# gazette Bm E G A Bm Tatoe owaru koto no nai kanashimi ga anata ubatte mo G F# Bm E G A Bm Hanare. Pound the Alarm digital sheet music. Special thanks to Dustin Yee for gazette gazette creating the music sheet and letting me use it for this vid! Purchase download play digital sheet music today at Sheet Music Plus. Gazette - Shiver shiver by shiver Gazette. the GazettE~ Toxic~ Band Score Book shiver JAPAN Visual Kei Sheet Music Book See more. Bird- Black Butler II anime gazette Numbered Musical Notation Preview ( Total 4 ) NO. net/ music/ anime/. The GazettE - Shiver - shiver Synthesia. Numbered Musical Notation Preview 1. the GazettE is a visual kei shiver rock band from Japan. The GazettE- Shiver New Maxi- single " Shiver" / Ost. Play more, gazette pay less with PASS: Unlimited online sheet music + 50% off all downloads shiver Try it free for 7 days Get unlimited sheet music with PASS Try it free.
Download and Print Shiver sheet music for Ukulele by shiver Coldplay gazette from Sheet Music Direct. I found the midi here: agarrado. Kuroshitsuji 2 OP Chord by: RYD86 Intro: G A A# G F# Bm E G A Bm Tatoe owaru koto no nai. 1 product rating - The gazette Gazette Toxic Taiwan CD w/ Sticker Shiver Pledge Vortex. Learn this song on Jellynote with our interactive sheet music and tabs. Feb 02, · The GazettE- Shiver New Maxi- single " Shiver" / Ost. Sheet Music and Tabs for the GazettE.
Download Shiver sheet music instantly - Piano, Piano Solo sheet music by Christine Brown: Christine Brown. This sample may show words spelled like this " Xxxxx". They formed in under the name ガゼット, though later changed the name to the Gazette in. Play along with youtube video covers. Choose determine which version of Shiver chords tabs by Gazette you can play. Subscribe Subscribed. The gazette shiver sheet music. Ab F Cm Bb Eb C Gm G Fm Bbm Db] gazette shiver Chords for Filth in the Beauty - The Gazette with capo transposer play along with guitar, piano ukulele & mandolin.
Ichigo' s Sheet Music is home to one of the largest collections of free Game and Anime sheet music on the web! StudioEpisode 11 How Do I Download shiver Music To My Ipad For Free Aoa Ft Takanori Nishikawa Mp3 Happy Birthday Bass Sheet. I just took the midi file and played it gazette on synthesia. The gazette shiver sheet music. Contains printable sheet music plus an interactive, downloadable digital sheet music file. Ichigo' s specializes in Anime Game sheet music, covering everything from individual arrangements for piano, violin voice to large scores for an shiver orchestra. Download Bird sheet music now! SHIVER - the GazettE - free sheet music drums , overdrive guitar, tabs for gazette solo voice, picked bass distortion guitar. gazette In the purchased product these words will not be X' d out. DISCLAIMER: I do not own anything. Contains complete lyrics This product is available worldwide * May not be appropriate for children.
Check out Shiver by THE GAZETTE on Amazon Music. Stream ad- free or purchase CD' s and MP3s now on Amazon. Get the best Shiver Guitar Pro tab by Gazette @ 911Tabs. Com - tabs search engine. Last updated on 10.
All types guitar guitar pro bass sheet music. Shiver Chords - Gazette, version ( 1). Play Shiver Chords using simple video lessons.
Home » G » Gazette » Gazette - Shiver Chords. Shiver digital sheet music.


Image Title: The Best Chair Glides For Hardwood Floors See List On All With Regard To Wood Decor 2. Post Title: Chair Glides For Wood Floors. Filename: the-best-chair-glides-for-hardwood-floors-see-list-on-all-with-regard-to-wood-decor-2.gif. Image Dimension: 279 x 197 pixels. Images Format: jpg/jpeg. Publisher/Author: Efrain Farrell. Uploaded Date: Saturday - September 15th. 2018 01:53:08 AM. Category: Architecture. Image Source: diy.com. 2530 Soft Glide Chair Inside Glides For Wood Floors Plan 7. Chair Glides For Hardwood Floors JPeMarket Within Wood Ideas 6. The Best Chair Glides For Hardwood Floors See List On All With Regard To Wood Decor 2. The Best Chair Glides For Minimizing Scratches Fine Homebuilding In Wood Floors Decor 0. Nail On Furniture Glides 8 Blanket Wood Floor Protector Chair Table Pertaining To For Floors Decor 18. Furniture Floor Glides Swivel Chair Glide Inside For Wood Floors Designs 1. Chair Glides For Wood Floors Ideas Intended Plan 15. The Best Chair Glides For Hardwood Floors See List On All Throughout Wood Decor 19. Chair Glides For Wood Floors Ideas In Remodel 11. Chair Glides Wood Floors Http Lingoflamingo Org Pinterest Woods Inside For Designs 3.